AnaptysBio

ANAB · NASDAQ

$45.43−$3.81 (−7.74%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $49.24

About ANAB

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).

Employees: 104
Headquarters: San Diego, California
Listed: Jan 26, 2017
Sector: Health Care
Industry: Biotechnology
Website: anaptysbio.com

Leadership

AnaptysBio executives
Name	Title	Since	Age
John Orwin	—	—	63
Daniel Faga	—	2021	45
Dennis Mulroy	—	—	70
Paul Lizzul	—	—	50
Eric Loumeau	—	—	62
Dennis Fenton	—	—	73
Rita Jain	—	—	62
Magda Marquet	—	—	66
Oleg Nodelman	—	—	48
Hollings Renton	—	—	78
John Schmid	—	—	62
J. Anthony Ware	—	—	72

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

AnaptysBio suppliers and customers
Company	Relationship	Country	Correlation
Merck MRK.DE	Supplier and customer	DE	0.66
Power POW.TO	Customer	CA	0.59
GlaxoSmithKline GSK.L	Supplier and customer	GB	-0.03
Bristol-Myers Squibb BMY	Supplier and customer	US	-0.67
TESARO, Inc. TSRO	Supplier and customer	US	—
UK Research & Innovation	Supplier and customer	GB	—

Similar companies

Companies in the same industry as AnaptysBio

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.